<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Second-generation (atypical) antipsychotic medication poisoning
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Second-generation (atypical) antipsychotic medication poisoning
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Second-generation (atypical) antipsychotic medication poisoning
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Raffi Kapitanyan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark K Su, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michele M Burns, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michelle Ruha, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 20, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A second-generation of antipsychotic medications, commonly referred to as "atypical antipsychotics," was introduced in 1998. The term "atypical" refers to an antipsychotic medication that produces minimal extrapyramidal side effects (EPS) at clinically effective antipsychotic doses, has a low propensity to cause tardive dyskinesia (TD) with long-term treatment, and treats both positive and negative signs and symptoms of schizophrenia [
         <a href="#rid1">
          1
         </a>
         ]. Atypical agents currently available include
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         (Clozaril),
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         (Risperdal),
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         (Zyprexa),
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         (Seroquel),
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         (Geodon),
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         (Abilify), and
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          paliperidone
         </a>
         (Invega), the active metabolite of risperidone. Some newer atypical antipsychotics include
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          asenapine
         </a>
         (Saphris),
         <a class="drug drug_general" data-topicid="9087" href="/z/d/drug information/9087.html" rel="external">
          iloperidone
         </a>
         (Fanapt) and
         <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">
          lurasidone
         </a>
         (Latuda).
        </p>
        <p>
         Atypical antipsychotics have largely replaced traditional agents as first-line therapy in the treatment of schizophrenia. Toxicologic exposures and fatalities associated with atypical agents pose a persistent problem in the United States and elsewhere [
         <a href="#rid2">
          2-4
         </a>
         ]. Consequently, it is important for the practicing clinician to be familiar with the pharmacology and toxicology of these medications.
        </p>
        <p>
         This topic review will discuss the basic pharmacology, presentation, and management of acute intoxication with atypical antipsychotics. Discussions of the clinical use of these drugs, details concerning potential side effects, and general management of drug overdose are found elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14773.html" rel="external">
          "First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PHARMACOLOGY AND CELLULAR TOXICOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pharmacology of atypical antipsychotic agents is complex. As a general rule, all exhibit dopamine (D2) receptor blockade, similar to first-generation antipsychotics, but with a lower binding affinity [
         <a href="#rid5">
          5
         </a>
         ]. In addition to lower D2 receptor potency and occupancy at therapeutic doses, atypical agents selectively antagonize mesolimbic D2 receptors more so than those in the nigrostriatum and prefrontal cortex. As a result, side effects attributable to nigrostriatal D2 blockade (eg, extrapyramidal symptoms, such as acute dystonia, parkinsonism, akathisia, and tardive dyskinesia) occur less frequently, as do side effects attributable to mesocortical (ie, prefrontal) D2 blockade (eg, neurocognitive impairment and negative symptoms).
        </p>
        <p>
         Atypical antipsychotics are also serotonin (5-HT) antagonists at the 5-HT2A receptor subtype. This pharmacologic effect mitigates the negative signs and symptoms of schizophrenia by disinhibiting the dopamine system in the nigrostriatum and prefrontal cortex [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Serotonin-dopamine antagonism is the reason why atypical antipsychotics may be given at smaller doses, producing fewer extrapyramidal side effects, while maintaining clinical efficacy [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         In addition to the common mechanisms noted above, each atypical agent has a unique pharmacodynamic profile that can be used to predict adverse effects in both therapeutic use and overdose. Although each agent has different affinities for specific receptors, most drugs fall into one of two groups. The first group consists of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , all of which demonstrate multiple receptor antagonism (alpha-1, histamine-1, and muscarinic-1). The second group consists of
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          paliperidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         , which demonstrate alpha-1 adrenergic and histamine-1 receptor antagonism [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         The atypical antipsychotic
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         possesses a unique receptor profile. Postsynaptic partial dopamine agonism blunts positive symptoms, while basal D2 receptor activation produces fewer movement disorders than nonspecific dopamine antagonists [
         <a href="#rid8">
          8,9
         </a>
         ]. Aripiprazole also binds to presynaptic dopamine autoreceptors, reducing dopamine release and synthesis [
         <a href="#rid8">
          8,9
         </a>
         ]. These pre- and postsynaptic actions result in a neurotransmitter-level stabilizing effect, blunting excess activity and augmenting deficient activity. Aripiprazole also has a low affinity for serotonin, alpha-1 adrenergic, and histamine-1 receptors. This novel receptor affinity pattern explains the efficacy and favorable side effect profile of this agent [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         The newer antipsychotics also have some unique features [
         <a href="#rid10">
          10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9087" href="/z/d/drug information/9087.html" rel="external">
          Iloperidone
         </a>
         has low antimuscarinic receptor and antihistaminic receptor activity and should result in less tachycardia sedation and agitation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          Asenapine
         </a>
         is taken via the sublingual route. If swallowed, its bioavailability significantly decreases from 35 to 2 percent. It has high affinity and antagonism for serotonin, alpha adrenergic, dopamine and histamine receptors but not muscarinic receptors. Consequently, hypotension and sedation are more likely to occur without tachycardia or agitation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">
          Lurasidone
         </a>
         possesses potent alpha-2C adrenoreceptor antagonism and low alpha-1 adrenergic antagonism. This may result in less hypotension. The alpha-2C adrenoreceptor is located presynaptically and functions as an inhibitory autoreceptor similar to alpha-2A adrenoreceptors, preventing
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         release.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PHARMACOKINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical antipsychotics are completely and rapidly absorbed after oral administration, but undergo significant first-pass hepatic metabolism  (
         <a class="graphic graphic_table graphicRef60825" href="/z/d/graphic/60825.html" rel="external">
          table 1
         </a>
         ). Time to peak plasma concentration ranges from 1 to 10 hours. Atypical antipsychotics have a large volume of distribution. They are highly lipophilic, highly protein-bound, and accumulate in the brain, lung, and other tissues. Plasma concentrations with therapeutic dosing are quite low (nanograms per milliliter). These agents enter breast milk and fetal circulation.
        </p>
        <p>
         The liver metabolizes atypical antipsychotics predominantly via cytochrome P450 enzymes (isoenzymes 1A2, 2D6, and 3A4). Therefore, serum levels may be affected by other medications that stimulate or inhibit the cytochrome P450 system.
        </p>
        <p>
         Some atypical agents have active metabolites. Long elimination half-lives and active metabolites allow for once or twice-daily therapeutic dosing. The correlation between doses, serum concentration, and clinical effects is quite variable. Fetuses, infants, and the elderly have less ability to metabolize these agents because of decreased cytochrome p450 activity, while children metabolize them more rapidly [
         <a href="#rid11">
          11,12
         </a>
         ]. While
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         is subject to drug interactions affecting the CYP2D6 enzyme, in vivo studies suggest this isozyme plays a limited role in the clearance of
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          paliperidone
         </a>
         , the major active metabolite of risperidone. This property of paliperidone makes dose adjustment unnecessary in patients with mild to moderate hepatic impairment.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES OF OVERDOSE
         </span>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         In acute overdose, atypical antipsychotics cause only mild to moderate toxicity in the majority of patients, and may produce no symptoms  (
         <a class="graphic graphic_table graphicRef60456" href="/z/d/graphic/60456.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid5">
          5,13
         </a>
         ]. Although the number of reported exposures has increased dramatically, mortality remains low [
         <a href="#rid4">
          4,14
         </a>
         ]. Toxic effects that do occur following overdose are largely an extension of a drug's physiologic effects  (
         <a class="graphic graphic_table graphicRef62403" href="/z/d/graphic/62403.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Pharmacology and cellular toxicology'
         </a>
         above and
         <a class="local">
          'History and physical examination'
         </a>
         below.)
        </p>
        <p>
         The toxic and lethal doses of atypical antipsychotics are highly variable and depend largely on the specific drug, the presence of co-intoxicants, age, and whether the patient is taking the drug for the first time. Children and unhabituated adults are more sensitive to the toxic effects of these agents. (See
         <a class="local">
          'Pediatric considerations'
         </a>
         below.)
        </p>
        <p>
         Toxicity from atypical antipsychotics usually begins within one to two hours and peaks by four to six hours following ingestion, and the effects are similar for both adults and children. Resolution of toxicity usually occurs by 12 to 48 hours following ingestion but has reportedly taken up to six days [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of atypical antipsychotic overdose is primarily based upon a history of ingestion and clinical findings. Central nervous system (CNS) effects occur most frequently  (
         <a class="graphic graphic_table graphicRef62403" href="/z/d/graphic/62403.html" rel="external">
          table 3
         </a>
         ). Extrapyramidal side effects (EPS) and neuroleptic malignant syndrome (NMS) are infrequent, but are more common in children [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         .)
        </p>
        <p>
         The most common clinical presentation consists of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lethargy and sedation (from histamine blockade)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Miosis, tachycardia, and orthostatic hypotension (from alpha adrenergic blockade)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticholinergic toxicity, including confusion (from muscarinic blockade) (see
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Certain effects may be more common with specific agents. A large retrospective case series found that
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         overdose appears more likely to cause respiratory depression, depressed mental status, and hypotension compared to other antipsychotics [
         <a href="#rid14">
          14
         </a>
         ]. Numerous case reports have described rapid fluctuations between sedation and agitation in
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         overdose, deemed "agitation despite sedation." The incidence of seizures is higher for
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         (10 percent) than for most atypical agents (less than 1 percent) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The pharmacology of atypical antipsychotics is complex, and presentations of patients who have overdosed on these drugs vary, especially if the patient has ingested a multiple receptor antagonist (eg,
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         or
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ). The development of pharmacobezoars following overdose of extended release formulations of
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         has been reported [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="local">
          'Pharmacology and cellular toxicology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2535.html" rel="external">
          "Gastric bezoars"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Possible historical features
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CNS – Fatigue/lethargy/sedation/agitation, confusion, dizziness, slurred speech, seizure, delirium, coma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiopulmonary – Dyspnea, chest pain, palpitations
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticholinergic manifestations – Blurry vision, dry mouth, constipation, urinary retention
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal (rare) – Nausea, vomiting, abdominal pain
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Possible examination findings
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CNS – Miosis (sometimes mydriasis), ataxia, dysarthria, dystonia, hypotonia, extrapyramidal side effects (eg, acute dystonia, parkinsonism, akathisia, tardive dyskinesia), rapidly fluctuating mental status (depression and agitation), hypersalivation, myoclonus, seizures, coma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiopulmonary – Tachycardia, orthostatic hypotension/mild hypertension, respiratory depression
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticholinergic – Facial flushing, dry mucous membranes, decreased sweating, mild hyperthermia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal – Abdominal tenderness, usually localized to the right upper quadrant, decreased bowel sounds
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H520461319">
         <span class="h1">
          LABORATORY EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine laboratory evaluation of the poisoned patient includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          Acetaminophen
         </a>
         and salicylate levels, to rule out these common coingestions
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiogram (ECG), to rule out conduction system poisoning by drugs that affect the QRS or QTc intervals
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy test in women of childbearing age
        </p>
        <p>
        </p>
        <p>
         No specific clinically useful test for atypical antipsychotic intoxication exists. Of note, atypical antipsychotics, particularly
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , may produce a false positive test for tricyclic antidepressants [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Sinus tachycardia is the most common abnormal ECG finding, but other aberrations can occur. These include dose-related repolarization abnormalities (QTc prolongation, ST depression, T wave flattening) and supraventricular/ventricular dysrhythmias [
         <a href="#rid5">
          5
         </a>
         ]. Such ECG findings are usually clinically insignificant, despite some cases of QTc prolongation.
        </p>
        <p>
         Of the atypical antipsychotics that increase the QTc interval,
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         are all associated with this ECG finding, but only quetiapine and risperidone are associated with an increased risk of developing Torsades de pointes [
         <a href="#rid18">
          18
         </a>
         ].
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          Aripiprazole
         </a>
         did not cause QTc prolongation or cardiotoxicity in preclinical trials or in the few published case reports of drug toxicity  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid15">
          15,19-33
         </a>
         ].
        </p>
        <p>
         Although unrelated to overdose, certain atypical agents have been shown to increase serum prolactin levels (
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ), cause hyperglycemia (
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ), increase liver transaminases (clozapine, olanzapine,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , risperidone, and
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         ), and induce agranulocytosis or leukopenia/neutropenia (clozapine and olanzapine) [
         <a href="#rid34">
          34-37
         </a>
         ]. Most of these effects are idiosyncratic.
        </p>
        <p>
         Additional testing may be needed depending upon the clinical situation, such as creatine phosphokinase and urine myoglobin in a patient found down and at risk for rhabdomyolysis, cerebrospinal fluid analysis in a patient with altered mental status of unclear etiology, or liver transaminases in a patient with significant abdominal pain.
        </p>
        <p>
         Qualitative screening by gas chromatography/mass spectrometry may be used to confirm the presence of atypical agents, but this is almost never clinically indicated. Quantitative drug concentrations are not generally used, since they are not readily available and do not predict toxicity or guide treatment [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H520461184">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of second-generation (atypical) antipsychotic poisoning is made clinically based upon a history of ingestion and suggestive clinical findings. A definitive diagnosis may be established using gas chromatography/mass spectrometry, but this is almost never clinically indicated and the results typically cannot be obtained in time to affect management. The most common clinical findings associated with atypical antipsychotic poisoning include lethargy and sedation; miosis, tachycardia, and orthostatic hypotension; and, anticholinergic toxicity. Effects can vary by agent. (See
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical antipsychotics interact with multiple receptors. Therefore, signs and symptoms of atypical antipsychotic overdose are similar to those seen with many other agents, which can make differentiation among potential poisons difficult. Below is a list of drugs commonly encountered in the overdose patient and the potential manifestations of acute intoxication they share with atypical antipsychotics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Traditional antipsychotics  (
         <a class="graphic graphic_table graphicRef60456" href="/z/d/graphic/60456.html" rel="external">
          table 2
         </a>
         ): extrapyramidal side effects (EPS), tardive dyskinesia (TD), neuroleptic malignant syndrome (NMS), anticholinergic, alpha adrenergic-blockade, prolonged QTc, CNS/respiratory depression (see
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cyclic antidepressants (
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          desipramine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         ): sedation, prolonged QRS/QT (see
         <a class="medical medical_review" href="/z/d/html/295.html" rel="external">
          "Tricyclic antidepressant poisoning"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticonvulsants (
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         ): CNS/respiratory depression (see
         <a class="medical medical_review" href="/z/d/html/312.html" rel="external">
          "Phenytoin poisoning"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antihistamines (
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         ): anticholinergic, sedation, prolonged QRS (see
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opioids (
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ): miosis, CNS/respiratory depression (see
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Muscle relaxants (
         <a class="drug drug_general" data-topicid="9306" href="/z/d/drug information/9306.html" rel="external">
          cyclobenzaprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9691" href="/z/d/drug information/9691.html" rel="external">
          metaxalone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9628" href="/z/d/drug information/9628.html" rel="external">
          methocarbamol
         </a>
         ): sedation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedative/hypnotics (
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         ): CNS/respiratory depression
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ethanol/toxic alcohols (ethylene glycol, methanol): CNS/respiratory depression (see
         <a class="medical medical_review" href="/z/d/html/336.html" rel="external">
          "Methanol and ethylene glycol poisoning: Pharmacology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/333.html" rel="external">
          "Ethanol intoxication in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antidysrhythmics (
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ): dysrhythmia, prolonged QRS/QT
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          General management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment for atypical antipsychotic overdose is primarily supportive. The general approach to any poisoned patient begins with stabilization of the airway, breathing, and circulation. General discussions of the management of poisoning are found elsewhere. Detailed management of intoxication with second-generation antipsychotics is discussed immediately below. A summary table of signs and symptoms is provided  (
         <a class="graphic graphic_table graphicRef62403" href="/z/d/graphic/62403.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">
          "Initial management of the critically ill adult with an unknown overdose"
         </a>
         .)
        </p>
        <p>
         Every patient requires continuous cardiac monitoring, intravenous (IV) access, an electrocardiogram (ECG), and continual reevaluation for mental status changes. Altered mental status can range from profound depression to signs of extrapyramidal side effects (EPS), tardive dyskinesia (TD), neuroleptic malignant syndrome (NMS), or seizures  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid37">
          37,38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         .)
        </p>
        <p>
         Hypotension secondary to alpha adrenergic (alpha) blockade is treated initially with IV boluses of isotonic crystalloid. Refractory hypotension, due to peripheral alpha blockade by atypical antipsychotics, can usually be treated with vasoconstrictive alpha agonists such as
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         or
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         . Drugs with beta 2 agonist effects (eg,
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         ) should be avoided as they can exacerbate the vasodilatory effects of alpha blockade [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Cardiac dysrhythmias (supraventricular and ventricular) are treated according to standard advanced cardiac/pediatric life support guidelines, with a few exceptions. Antidysrhythmics that prolong the QTc interval, such as type IA (
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         ), IC (
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         ), and III (
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         ) medications should be avoided, as they may exacerbate conduction abnormalities. A type IB antidysrhythmic agent (eg,
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ) may be used. QRS prolongation may be treated with IV
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         , as with cyclic antidepressants and other Na+ channel blocking agents [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/295.html" rel="external">
          "Tricyclic antidepressant poisoning"
         </a>
         .)
        </p>
        <p>
         Seizures secondary to atypical antipsychotic toxicity are usually isolated and self-limited, and treatment with anticonvulsant agents is rarely needed. If treatment is necessary, benzodiazepines (such as
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ) are first-line therapy [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H55596405">
         <span class="h2">
          Decontamination and enhanced elimination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whenever feasible, we suggest a single dose of activated charcoal (AC) with or without a cathartic (eg,
         <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">
          sorbitol
         </a>
         ) be given as soon as the patient with second-generation antipsychotic poisoning has been stabilized [
         <a href="#rid40">
          40
         </a>
         ]. Gastric lavage is not recommended because these agents are associated with low mortality in overdose. AC should be withheld in patients who are sedated and may not be able to protect their airway, unless tracheal intubation is performed first. However, tracheal intubation should not be performed solely for the purpose of giving AC. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient"
         </a>
         .)
        </p>
        <p>
         The high-protein binding, large volume of distribution, and low plasma levels of atypical antipsychotics make extracorporeal removal, by either hemodialysis or hemoperfusion, unlikely to be of benefit [
         <a href="#rid37">
          37
         </a>
         ]. We do not recommend its use.
        </p>
        <p class="headingAnchor" id="H55596380">
         <span class="h2">
          Extrapyramidal and anticholinergic effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute extrapyramidal side effects (eg, dystonia) due to second-generation antipsychotic poisoning may be treated with anticholinergic agents, such as
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         or
         <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">
          benztropine
         </a>
         . Patients with neuroleptic malignant syndrome require supportive treatment, which may include active cooling, benzodiazepines,
         <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">
          bromocriptine
         </a>
         , or neuromuscular blockade, depending upon the degree of symptoms. Treatment for tardive dyskinesia includes benzodiazepines and supportive care [
         <a href="#rid41">
          41,42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">
          "Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4908.html" rel="external">
          "Tardive dyskinesia: Prevention, treatment, and prognosis"
         </a>
         .)
        </p>
        <p>
         Anticholinergic effects of atypical antipsychotics may contribute to the severe agitation and altered level of consciousness seen in acute overdose. Benzodiazepines are usually adequate to control these symptoms.
         <a class="drug drug_general" data-topicid="9770" href="/z/d/drug information/9770.html" rel="external">
          Physostigmine
         </a>
         , a short-acting acetylcholinesterase inhibitor, has been successfully used to reverse the anticholinergic syndrome seen with
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         [
         <a href="#rid43">
          43-45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9770" href="/z/d/drug information/9770.html" rel="external">
          Physostigmine
         </a>
         has potential adverse effects (bradycardia, bronchospasm, bradypnea), and its use as an antidote for atypical antipsychotic overdose is not clearly defined. We recommend that physostigmine only be used in the treatment of atypical antipsychotic poisoning in consultation with a medical toxicologist or poison control center. Patients with cyclic antidepressant toxicity should not receive physostigmine [
         <a href="#rid43">
          43,44,46
         </a>
         ]. Anticholinergic toxicity and physostigmine therapy are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning", section on 'Antidotal therapy with physostigmine for severe toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H55596455">
         <span class="h2">
          Refractory toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the rare case of severe poisoning from a second-generation antipsychotic that fails to improve with the standard treatments described above, lipid emulsion therapy may be useful. However, support for this intervention consists solely of case reports and we cannot recommend routine treatment with lipid emulsion [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Disposition
         </span>
         <span class="headingEndMark">
          —
         </span>
         Second-generation antipsychotic agents are associated with a rapid onset of symptoms following overdose, so disposition is generally determined within six hours of ingestion. Patients who remain asymptomatic after a six-hour observation period require no further medical evaluation, assuming no cardiac conduction abnormalities develop during the observation period and no other significant clinical issues are present. Psychiatry consultation is needed for suicidal patients. Patients with moderate to severe toxicity (CNS/respiratory depression, hypotension, agitation/delirium, dysrhythmias) should be admitted to a monitored bed or intensive care unit, depending on symptom severity.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          PEDIATRIC CONSIDERATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mental health clinicians are treating children and adolescents with atypical antipsychotics at increasing rates for a range of psychiatric illnesses, despite limited data on their efficacy in this age group [
         <a href="#rid49">
          49
         </a>
         ]. The diversity of indications has contributed to the increased use of these agents, and increased episodes of overdose. In the United States, approximately 6,000 annual exposures to atypical antipsychotic agents occur in children 19 years of age and younger; international data is limited. Significant adverse effects, including major outcomes and death, are uncommon in reported single exposures [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Among the newer antipsychotics,
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          asenapine
         </a>
         is indicated in children 10 years and older for bipolar I disorder. The other new agents,
         <a class="drug drug_general" data-topicid="9087" href="/z/d/drug information/9087.html" rel="external">
          iloperidone
         </a>
         and
         <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">
          lurasidone
         </a>
         , do not have this US Food and Drug Administration (FDA)-approved pediatric indication.
        </p>
        <p>
         Most published reports of overdose do not contain data on long-term consequences and are unable to provide conclusions about the significance of blood levels, the differences in duration of symptoms by age or size, or the relationship between the severity of symptoms and the dose ingested. Assessment and management in children is similar to that of adults; history and clinical presentation remain paramount. The most frequent clinical presentation of overdose in children includes nausea and vomiting, lethargy, drowsiness, somnolence, tachycardia, and central nervous system (CNS) depression [
         <a href="#rid8">
          8,13,38,50
         </a>
         ].
        </p>
        <p>
         Children may be at increased risk of toxicity with atypical antipsychotics. Children metabolize these drugs more rapidly, and, because children generally have less adipose tissue and lower levels of protein-binding, consequently there may be increased drug bioavailability [
         <a href="#rid37">
          37
         </a>
         ]. Therefore, we suggest that children who have ingested atypical antipsychotic medications and are asymptomatic be observed for six hours. Clinicians should maintain a low threshold for admitting mildly symptomatic children.
        </p>
        <p>
         Supportive treatment and close observation are the mainstays of management.
         <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">
          Sorbitol
         </a>
         should not be given to young children because of the risk of excessive fluid loss. As with adults, the majority of toxicity in children due to atypical antipsychotics results in good outcomes [
         <a href="#rid13">
          13,50
         </a>
         ]. Nevertheless, a small number of case reports describe instances when endotracheal intubation and admission to an intensive care unit were necessary [
         <a href="#rid51">
          51,52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15126944">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H205003771">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3833544340">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">
          "Society guideline links: General measures for acute poisoning treatment"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First- versus second-generation antipsychotics
         </strong>
         – Atypical (second-generation) antipsychotic medications have largely replaced conventional first-generation medications for the treatment of schizophrenia because of their effectiveness and safer therapeutic and overdose profile  (
         <a class="graphic graphic_table graphicRef60456" href="/z/d/graphic/60456.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacology
         </strong>
         – The pharmacology of atypical antipsychotic agents is complex, involving several types of receptors. They all exhibit dopamine (D2) receptor blockade, similar to first-generation antipsychotics, but with a lower binding affinity. They are also antagonists at serotonin (5-HT), alpha-1, histamine-1, and muscarinic-1 receptors, with each having a unique pharmacodynamic profile that can be used to predict adverse effects in both therapeutic use and overdose  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Pharmacology and cellular toxicology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features of overdose
         </strong>
         – In acute overdose, atypical antipsychotics cause only mild to moderate toxicity in the majority of patients and may produce no symptoms. The toxic and lethal doses of atypical antipsychotics are highly variable and depend largely on the specific drug, the presence of co-intoxicants, patient age, and whether the patient is taking the drug for the first time  (
         <a class="graphic graphic_table graphicRef62403" href="/z/d/graphic/62403.html" rel="external">
          table 3
         </a>
         ). Children and unhabituated adults are more sensitive to the toxic effects of these agents. Atypical antipsychotics can cause a range of signs and symptoms, most often involving the central nervous system. The most common clinical presentation consists of (see
         <a class="local">
          'Clinical features of overdose'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lethargy and sedation (from histamine blockade)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Miosis, tachycardia, and orthostatic hypotension (from alpha adrenergic blockade)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anticholinergic toxicity, including confusion (from muscarinic blockade)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effects from specific agents
         </strong>
         – Certain effects in acute overdose may be more common with specific agents (see
         <a class="local">
          'History and physical examination'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Olanzapine – Rapid fluctuations between sedation and agitation can occur
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clozapine – More often associated with seizures, although they are still uncommon
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ziprasidone – Greatest effect on the QTc interval
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Signs and symptoms of atypical antipsychotic overdose are shared by many agents, which can make differentiation among potential poisons difficult. Drugs commonly encountered in the overdose patient that may share manifestations of acute intoxication with atypical antipsychotics include traditional antipsychotics, cyclic antidepressants, anticonvulsants, antihistamines, opioids, muscle relaxants, sedative/hypnotics, ethanol/toxic alcohols, and antidysrhythmics. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory evaluation
         </strong>
         – Obtain an electrocardiogram (ECG), salicylate and
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         concentrations, a fingerstick glucose, and a qualitative pregnancy test in females of childbearing age. Obtain liver transaminases and a complete blood count in patients with altered mental status, abdominal pain, or other concerning findings (eg, possible acetaminophen co-ingestion). (See
         <a class="local">
          'Laboratory evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of atypical antipsychotic poisoning is made clinically based upon a history of ingestion and suggestive clinical findings. No specific, clinically useful test to identify atypical antipsychotic intoxication exists. A definitive diagnosis may be established using gas chromatography/mass spectrometry, but this is almost never clinically indicated, and the results typically cannot be obtained in time to affect management. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of atypical antipsychotic overdose is primarily supportive. Care includes continuous cardiac monitoring, intravenous (IV) access, and continual reevaluation for mental status. Management of specific findings includes the following (see
         <a class="local">
          'General management'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypotension is treated initially with IV crystalloid. Refractory hypotension due to peripheral alpha-adrenergic blockade can usually be treated with vasoconstrictive alpha agonists such as
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         or
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Seizures are generally brief and self-limited but may be treated with benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ) if necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute extrapyramidal side effects (eg, dystonia) may be treated with anticholinergic agents such as
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         or
         <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">
          benztropine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal decontamination
         </strong>
         – In a patient with an acute overdose of an atypical antipsychotic medication, we suggest giving a single dose of activated charcoal (AC) with or without a cathartic (eg,
         <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">
          sorbitol
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). AC should be withheld in patients who are sedated and may not be able to protect their airway, unless tracheal intubation is performed first. Tracheal intubation should not be performed solely for the purpose of giving AC. (See
         <a class="local">
          'Decontamination and enhanced elimination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pediatric considerations
         </strong>
         – Children may be at increased risk of toxicity following atypical antipsychotic ingestion. We suggest that children who have ingested atypical antipsychotic medications and are asymptomatic be observed for six hours. Clinicians should maintain a low threshold for admitting mildly symptomatic children. Management is otherwise similar to adults. (See
         <a class="local">
          'Pediatric considerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disposition
         </strong>
         – Patients who remain asymptomatic after a six-hour observation period require no further medical evaluation, assuming no cardiac conduction abnormalities develop during the observation period and no other significant clinical issues are present. Patients with moderate to severe toxicity should be admitted to a monitored bed or intensive care unit, depending on symptom severity. (See
         <a class="local">
          'Disposition'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Freedman R. Schizophrenia. N Engl J Med 2003; 349:1738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill JS, Pillai SK, Koh OH, Jambunathan S. [Non-fatal paliperidone overdose: a case report]. Turk Psikiyatri Derg 2010; 21:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mowry JB, Spyker DA, Cantilena LR Jr, et al. 2012 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 30th Annual Report. Clin Toxicol (Phila) 2013; 51:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol 2001; 39:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60 Suppl 10:5.
          </a>
         </li>
         <li class="breakAll">
          B, Thakurta S. Drug Class Review: Atypical Antipsychotic Drugs: Final Report Update 2. Portland, (OR): Oregon Health &amp; Science University; 2008 Jun. www.ohsu.edu/drugeffectiveness/reports/final.cfm.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lofton AL, Klein-Schwartz W. Atypical experience: a case series of pediatric aripiprazole exposures. Clin Toxicol (Phila) 2005; 43:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seifert SA, Schwartz MD, Thomas JD. Aripiprazole (abilify) overdose in a child. Clin Toxicol (Phila) 2005; 43:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orsolini L, Tomasetti C, Valchera A, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 2016; 15:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamminga CA. Similarities and differences among antipsychotics. J Clin Psychiatry 2003; 64 Suppl 17:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang J, Gorrod JW. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol 1999; 19:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meli M, Rauber-Lüthy C, Hoffmann-Walbeck P, et al. Atypical antipsychotic poisoning in young children: a multicentre analysis of poisons centres data. Eur J Pediatr 2014; 173:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ngo A, Ciranni M, Olson KR. Acute quetiapine overdose in adults: a 5-year retrospective case series. Ann Emerg Med 2008; 52:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trenton A, Currier G, Zwemer F. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 2003; 17:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rauber-Lüthy C, Hofer KE, Bodmer M, et al. Gastric pharmacobezoars in quetiapine extended-release overdose: a case series. Clin Toxicol (Phila) 2013; 51:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caravati EM, Juenke JM, Crouch BI, Anderson KT. Quetiapine cross-reactivity with plasma tricyclic antidepressant immunoassays. Ann Pharmacother 2005; 39:1446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aronow WS, Shamliyan TA. Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders. Ann Transl Med 2018; 6:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duggan L, Fenton M, Rathbone J, et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev 2005; :CD001359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004; :CD000967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000; :CD002306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayaram MB, Hosalli P. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2005; :CD005237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000; :CD001945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2004; :CD004578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollak PT, Zbuk K. Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. Clin Pharmacol Ther 2000; 68:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palenzona S, Meier PJ, Kupferschmidt H, Rauber-Luethy C. The clinical picture of olanzapine poisoning with special reference to fluctuating mental status. J Toxicol Clin Toxicol 2004; 42:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balicka-Slusarczyk B, Szczeklik J, Szpak D, Groszek B. [Clinical course of acute poisoning with olanzapine]. Przegl Lek 2005; 62:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodge CH, Jewell M, Gummin DD, Leikin JB. Atypical presentation of risperidone toxicity. Vet Hum Toxicol 2001; 43:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magdalan J, Wasyko-Smolarek M, Antończyk A, et al. [Intoxications with atypical antipsychotic drugs--data of the Acute Intoxication Unit in Wrocław]. Przegl Lek 2004; 61:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chue P, Singer P. A review of olanzapine-associated toxicity and fatality in overdose. J Psychiatry Neurosci 2003; 28:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton S, Heslop K, Harrison K, Barnes M. Ziprasidone overdose. Am J Psychiatry 2000; 157:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           House M. Overdose of ziprasidone. Am J Psychiatry 2002; 159:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biswas AK, Zabrocki LA, Mayes KL, Morris-Kukoski CL. Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J Toxicol Clin Toxicol 2003; 41:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liberty IF, Todder D, Umansky R, Harman-Boehm I. Atypical antipsychotics and diabetes mellitus: an association. Isr Med Assoc J 2004; 6:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161:1709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stergiou V, Bozikas VP, Garyfallos G, et al. Olanzapine-induced leucopenia and neutropenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubois D. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Curr Opin Pediatr 2005; 17:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antia SX, Sholevar EH, Baron DA. Overdoses and ingestions of second-generation antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol 2005; 15:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capel MM, Colbridge MG, Henry JA. Overdose profiles of new antipsychotic agents. Int J Neuropsychopharmacol 2000; 3:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chyka PA, Seger D. Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997; 35:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanft A, Eggleston CF, Bourgeois JA. Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine. J Child Adolesc Psychopharmacol 2004; 14:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeBlaye I, Donatini B, Hall M, Krupp P. Acute overdosage with clozapine: A review of the available clinical experience. Pharmaceutical Med 1992; 6:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferraro KK, Burkhart KK, Donovan JW, et al. A retrospective review of physostigmine in olanzapine overdose. J Toxicol Clin Toxicol 2001; 39:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weizberg M, Su M, Mazzola JL, et al. Altered mental status from olanzapine overdose treated with physostigmine. Clin Toxicol (Phila) 2006; 44:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med 2000; 35:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartos M, Knudsen K. Use of intravenous lipid emulsion in the resuscitation of a patient with cardiovascular collapse after a severe overdose of quetiapine. Clin Toxicol (Phila) 2013; 51:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yurtlu BS, Hanci V, Gür A, Turan IO. Intravenous lipid infusion restores consciousness associated with olanzapine overdose. Anesth Analg 2012; 114:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catalano G, Catalano MC, Nunez CY, Walker SC. Atypical antipsychotic overdose in the pediatric population. J Child Adolesc Psychopharmacol 2001; 11:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catalano G, Cooper DS, Catalano MC, Butera AS. Olanzapine overdose in an 18-month-old child. J Child Adolesc Psychopharmacol 1999; 9:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theisen FM, Grabarkiewicz J, Fegbeutel C, et al. Olanzapine overdose in children and adolescents: two case reports and a review of the literature. J Child Adolesc Psychopharmacol 2005; 15:986.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 304 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14585943" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20028214" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21125508" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : [Non-fatal paliperidone overdose: a case report].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24359283" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : 2012 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 30th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11327216" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The pharmacology and toxicology of atypical antipsychotic agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10340682" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Receptor pharmacology of neuroleptics: relation to clinical effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10340682" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Receptor pharmacology of neuroleptics: relation to clinical effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15902787" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Atypical experience: a case series of pediatric aripiprazole exposures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15902794" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Aripiprazole (abilify) overdose in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27347638" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : An update of safety of clinically used atypical antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14680420" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Similarities and differences among antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10379422" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24370666" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Atypical antipsychotic poisoning in young children: a multicentre analysis of poisons centres data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18433934" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Acute quetiapine overdose in adults: a 5-year retrospective case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12665390" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Fatalities associated with therapeutic use and overdose of atypical antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24199644" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Gastric pharmacobezoars in quetiapine extended-release overdose: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16046487" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Quetiapine cross-reactivity with plasma tricyclic antidepressant immunoassays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29862236" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15846619" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Olanzapine for schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15106155" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Quetiapine for schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10908551" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Risperidone versus other atypical antipsychotic medication for schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15846745" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Risperidone versus olanzapine for schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11034737" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Ziprasidone for schizophrenia and severe mental illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15106256" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Aripiprazole for schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10945320" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15083933" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The clinical picture of olanzapine poisoning with special reference to fluctuating mental status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16225103" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : [Clinical course of acute poisoning with olanzapine].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11757991" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Atypical presentation of risperidone toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15521612" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : [Intoxications with atypical antipsychotic drugs--data of the Acute Intoxication Unit in Wrocław].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12921220" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A review of olanzapine-associated toxicity and fatality in overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10784487" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Ziprasidone overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12042202" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Overdose of ziprasidone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12733844" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cardiotoxicity associated with intentional ziprasidone and bupropion overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15151366" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Atypical antipsychotics and diabetes mellitus: an association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337666" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15950350" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Olanzapine-induced leucopenia and neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15800418" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16379518" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Overdoses and ingestions of second-generation antipsychotics in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11343578" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Overdose profiles of new antipsychotic agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9482427" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15119907" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Neuroleptic malignant syndrome and atypical antipsychotic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15650507" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Acute overdosage with clozapine: A review of the available clinical experience
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A retrospective review of physostigmine in olanzapine overdose
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16749552" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Altered mental status from olanzapine overdose treated with physostigmine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10736125" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23768031" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Use of intravenous lipid emulsion in the resuscitation of a patient with cardiovascular collapse after a severe overdose of quetiapine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22434897" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Intravenous lipid infusion restores consciousness associated with olanzapine overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15650494" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Second-generation antipsychotic medications in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11838825" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Atypical antipsychotic overdose in the pediatric population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10630456" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Olanzapine overdose in an 18-month-old child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16379519" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Olanzapine overdose in children and adolescents: two case reports and a review of the literature.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
